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ABSTRACT
While RNAi has traditionally relied on RNA duplexes,
early evaluation of siRNAs demonstrated activity of
the guide strand in the absence of the passenger
strand. However, these single strands lacked the
activity of duplex RNAs. Here, we report the system-
atic use of chemical modifications to optimize
single-strand RNA (ssRNA)-mediated mRNA
knockdown. We identify that 20F ribose modifica-
tions coupled with 50-end phosphorylation vastly
improves ssRNA activity both in vitro and in vivo.
The impact of specific chemical modifications on
ssRNA activity implies an Ago-mediated mechanism
but the hallmark mRNA cleavage sites were not
observed which suggests ssRNA may operate
through a mechanism beyond conventional Ago2
slicer activity. While currently less potent than
duplex siRNAs, with additional chemical optimiza-
tion and alternative routes of delivery, chemically
modified ssRNAs could represent a powerful RNAi
platform.
INTRODUCTION
RNA interference is a process inherently driven by RNA
duplexes. The double-strand endonuclease Dicer processes
long double-stranded RNAs (dsRNA) into small 21–23nt
RNA duplexes containing a 50 phosphate (1–4). The re-
sulting siRNAs and miRNAs load into the RNA-induced
silencing complex (RISC) where the passenger strand
(sense) is dissociated, leaving the active guide strand (anti-
sense) loaded in Ago2 and available to base pair with
target mRNAs and initiate degradation (5,6). Exogenous
delivery of small interfering dsRNAs (siRNAs) to mam-
malian cells was shown to be an effective strategy to
engage this endogenous mechanism of RNA-mediated
regulation (7,8). This seminal discovery resulted in
siRNA becoming an indispensible tool for studying
gene function and now represents a new therapeutic
modality (9,10).
Despite the central role of duplex RNAs in triggering
RNAi, in the early days of the development of siRNAs
there were reports of single-strand RNA (ssRNA) acting
to initiate mRNA knockdown. Using extracts from
human cell lines, Martinez et al. (11) reported that
ssRNA could reconstitute RISC; however, compared to
duplex siRNAs, 10- to 100-fold higher concentrations of
ssRNA were required. They also transfected single strands
and duplexes into cells, thus demonstrating that ssRNA
knockdown was optimal with a size >17nt and improved
by the addition of a 50 phosphate. Again, duplex siRNAs
remained more potent. Schwarz et al. (12) evaluated both
miRNA and siRNA, demonstrating that ssRNAs corres-
ponding to the let-7 miRNA or luciferase could trigger
target cleavage but required a 50 phosphate. The observa-
tion that phosphorylation improves ssRNA activity indir-
ectly argues for Ago-mediated activity. Phosphorylation
of the 50-end of the guide strand plays an important role
in guide strand binding within the MID domain of Ago2
and the subsequent positioning of the guide strand for
accurate cleavage (13,14).
Single-strand-mediated knockdown was shown to be
dose-dependent but was  8-fold less effective than the
corresponding duplex. Another study found that ssRNA
targeting the human blood clotting initiator tissue factor
(TF) was as effective in human cells as the duplex siRNA
at high concentrations of 100–200nM (15). In contrast to
other reports, exogenous phosphorylation of the ssRNA
was not found to improve knockdown activity. In a
follow-up study, a dose–response comparison of the
same single strand and duplex siRNAs found the
dsRNA was 5- to 6-fold more potent than the correspond-
ing ssRNA and analysis by northern blot demonstrated
that ssRNA produced mRNA cleavage fragments (16).
Core components of RISC have been shown to bind to
ssRNAs. In vitro binding studies with puriﬁed human
Ago2 demonstrate signiﬁcantly higher binding afﬁnity
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dsRNA (17). Recombinant Dicer has also been shown
to bind 21nt ssRNAs in vitro with preferential afﬁnity
for ssRNAs containing a 50 phosphate (18). This led the
authors to hypothesize that Dicer may play a role in
ssRNA knockdown by either facilitating loading of
ssRNA into Ago2 or by binding to ssRNAs and thus pro-
tecting them from nucleases (18).
Chemical modiﬁcations have been employed to improve
the pharmacokinetic properties of siRNAs including
increasing nuclease stability, improving potency,
reducing off target effects and abrogating immune stimu-
lation (19–21). Generally, 20 ribose modiﬁcations (20-
methoxy and 20-ﬂuoro in particular) are broadly tolerated
within the guide strand of duplex siRNAs. Holen et al.
reported the ﬁrst evaluation of the impact of chemical
modiﬁcations on ssRNA activity and compared them to
corresponding duplex siRNAs (16). The positional
chemical sensitivity seen for duplex siRNAs (15) was
mirrored by the ssRNAs which the authors interpret as
indicating ssRNA and dsRNA act through a common
RNAi pathway (16). This hypothesis was supported by
their observation that an excess of dsRNA can competi-
tively block the activity of ssRNAs in vitro (16).
Hall et al. (22) reported that ssRNA potency can be
signiﬁcantly improved by the replacement of some of
the phosphodiester backbone with boranophosphate
modﬁcations, where a non-bridging oxygen is replaced
with an isoelectronic borane. Inclusion of 5–8 borano-
phosphate modiﬁcations allowed ssRNAs to achieve
knockdown comparable to duplex siRNAs at  10–
25nM concentrations. Importantly, HeLa cells pre-
treated with siRNAs targeting Ago2 had signiﬁcantly
reduced target knockdown when they were subsequently
transfected with ssRNAs, suggesting that ssRNAs act
through Ago2 (22). Despite their beneﬁcial properties,
boranophosphate modiﬁcations present a number of syn-
thesis and chemistry challenges and have thus far not been
widely adopted (21).
Recently, in unpublished work presented at the 7th
Annual Oligonucleotide Therapeutics Society meeting
(September 2011), Swayze et al. (23) described a
modiﬁed ssRNA that included phosphorothioate back-
bone and 50-end vinyl phosphonate modiﬁcations that
were intended to improve the stability of the ssRNA
molecule. This modiﬁcation pattern was a reﬁnement of
an earlier published pattern of evenly spaced 20F and
20OMe modiﬁcations reported to improve the activity of
duplex siRNAs (24). Swayze et al. (23) also reported that
ssRNAs were inactive in Ago2 knockout cells indicating
Ago2 mediates ssRNA activity. Importantly, subcutane-
ously administered unformulated ssRNAs were active in
rodents and comparable to the potency of second gener-
ation RNase H antisense oligonucleotides.
As discussed above, the limited exploration of chemical
modiﬁcations has shown promise for improving the
activity of ssRNA. Therefore, we conducted a systematic
analysis of the impact of 20 ribose modiﬁcations on the ac-
tivity of both duplex and ssRNA-mediated knockdown—
screening six different RNAs to ensure the generality of
our observations. Modiﬁcations of the 20 ribose ring
included methoxy (20OMe), ﬂuoro (20F), and deoxy
(20H), which applied to either purines or pyrimidines
present on the guide strand. Additionally, guide strands
were synthesized with or without phosphorylation of the
50-end. In vitro screening in tissue culture cells identiﬁed
that 20F content and 50 phosphorylation are key for
optimal ssRNA-mediated knockdown of target mRNAs.
Optimized ssRNAs were tested in mice using a lipid
nanoparticle delivery vehicle. Knockdown of target
mRNA by ssRNA exceeded 90% at the highest dose
tested; however, the duplex siRNAs in the same study
had greater overall knockdown and much longer duration.
Modiﬁcation of the guide strand 50-end with abasic nu-
cleotides negatively impacted the activity of both duplex
and ssRNAs, consistent with an earlier report that an
abasic nucleotide reduced Ago2 binding afﬁnity and
cleavage activity (17). Taken together with the role of 50
phosphorylation, these observations offer indirect
evidence that ssRNAs act through an Ago-mediated
mechanism. However, analysis of cleavage products by
50RACE and sequencing failed to identify distinct
cleavage sites for ssRNAs despite the identiﬁcation of
hallmark Ago2 cleavage for duplex RNAs. This suggests
ssRNA may act through a mechanism beyond canonical
Ago2 slicer activity.
While 20-ﬂuoro content and 50 phosphorylation were
identiﬁed as greatly improving ssRNA activity, our side
by side comparison with duplex siRNAs demonstrates
that duplex RNAs are consistently more potent than
their corresponding single strands both in vitro and
in vivo. Importantly, as highlighted by preliminary
results from Swayze et al. (23), with further improvements
in chemical optimization and evaluation of alternative
dosing strategies, such as sub-cutaneous delivery, ssRNA
could represent a powerful alternative to duplex siRNAs.
MATERIALS AND METHODS
RNA oligo sequence and synthesis
A systematic screen of 20 ribose modiﬁcations on six dif-
ferent target sites (Table 1) resulted in a total of 180
siRNAs which were then compared as duplex and single
strands (360 in total). Individual sequences and modiﬁca-
tion patterns are listed in Supplementary Tables S3
and S4. Inverted abasic modiﬁcations present at the 50
and 30 of the passenger strand serve to block loading
into Ago2 (25,26). Sequences for siRNAs were selected
using a previously published algorithm developed to
Table 1. Target gene, site, accession and sequence for siRNAs
Target
gene
Target
site
Target
accession
Target sequence
ApoB 6981 NM_009693 CACAATGCATTTAGATCAA
ApoB 8786 NM_009693 CCAGTAAGGCTTCTCTTAA
ApoB 9470 NM_009693 CTTTAACAATTCCTGAAAT
ApoB 10127 NM_009693 TCATCACACTGAATACCAA
SSB 386 NM_009278 TAACAACAGACTTTAATGT
SSB 963 NM_009278 AAATCATGGTGAAATAAAA
4126 Nucleic Acids Research, 2012,Vol.40, No. 9predict maximal knockdown while minimizing off-target
hybridizations (27). siRNAs were synthesized using previ-
ously described methods (28,29). Individual oligonucleo-
tide strands were synthesized separately using solid-phase
methods, puriﬁed by ion-exchange chromatography
and duplexed when appropriate. Knockdown studies
were normalized using a non-targeting control siRNA
sequence which contains ribose 20OH (r), 20F (f), 20OMe
(m) and 20H (d) residues at the indicated positions as well
as inverted abasic caps (iB) on the passenger strand: guide
(50–30) (fC;fC;fU;mG;mA;mA;mG;mA;mG;mA;mG;fU;
fU;mA;mA;mA;rA;rG;rA;mU;mU) and passenger (50–30)
(iB;fU;fC;fU;fU;fU;fU;dA;dA;fC;fU;fC;fU;fC;fU;fU;fC;
dA;dG;dG;dT;dT;iB).
In vitro mRNA knockdown
Mouse Hepa1–6 cells were cultured in Dulbecco’s-
modiﬁed Eagle Medium supplemented with 10% fetal
bovine serum, 1% penicillin–steptomycin and 1%
sodium bicarbonate. These cells were plated in a 96-well
culture plates at a density of 3000 cells/well 24h prior to
transfection. Transfections were performed using
Opti-MEM I Reduced Serum Media and Lipofectamine
RNAiMAX as previously described (30). Final siRNA
concentrations range from 100 to 1nM for in vitro
cell-based screens with concentrations varying for
ssRNA (100nM, 10nM) and dsRNA (100nM, 10nM,
and 1nM) (see Supplementary Table S3). Final siRNA
concentrations for the dose–response curves range from
40 to 0.002nM along an eight-point, 4-fold titration
curve. Twenty-four hours post-transfection cells were
washed with phosphate-buffered saline and processed
using the TaqMan Gene Expression Cells-to-CT
(Invitrogen), per manufacturer’s instructions, to extract
RNA, synthesize cDNA and perform RT–qPCR using
an Ssb (Mm00447374_m1) or ApoB (Mm01545154_g1)
speciﬁc Taqman primer/probe set on an ABI Prism
7900HT Sequence Detector. Reverse transcription condi-
tions were as follows: 60min at 37 C followed by 5min
at 95 C. RT–qPCR conditions were as follows: 2min at
50 C, 10min at 95 C, followed by 40 cycles of 15s at
95 C, and 1min at 60 C. Gapdh mRNA levels were
used for data normalization (Taqman part number
4308313). Knockdown of Ssb/ApoB was calculated as
the percent knockdown in Ssb/ApoB cDNA measured in
experimentally treated cells relative to the Ssb/ApoB
cDNA levels measured in non-targeting, control-treated
cells. The comparative Ct calculation method for
knockdown has previously been described (31). Brieﬂy,
Ct=CtTarget mRNA CtGapdh and Ct=
Ct(siRNA) Ct(non-targeting control) and relative expres-
sion level=2
 Ct and % knockdown=
100 (1 2
 Ct). Potency (EC50) was calculated using
a four-parameter curve ﬁt tool and Prism graphing
software (GraphPad Software).
Lipid nanoparticle formulation
siRNA lipid nanoparticles (LNPs) were assembled by
simultaneous mixing of a lipid mixture in ethanol
with an aqueous solution of siRNA followed by
diaﬁltration as previously described (30,32). The cat-
ionic lipid CLinDMA (2-{4-[(3b)-cholest-5-en-3-yloxy]-
butoxy}-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-
yloxy]propan-1-amine), cholesterol and PEG-DMG
(monomethoxy(polyethyleneglycol)-1,2-dimyristoylglycer-
ol) were mixed together at a molar ratio of 50:44:6.
PEG-DMG was purchased from NOF Corporation, chol-
esterol from Northern Lipids, and CLinDMA was
synthesized by Merck & Co., Inc. Particle size was
measured by dynamic light scattering using a Wyatt
DynaPro plate reader and percent encapsulation was
determined using a SYBR Gold ﬂuorescence assay
(Invitrogen) and were within pre-established quality
metrics (32).
In vivo mRNA knockdown
All in vivo work was approved by an Institutional Animal
Care and Use Committee and adhered to standards rec-
ommended by the Association for Assessment and
Accreditation of Laboratory Animal Care, International.
C57/BL6 mice (Jackson Labs) were dosed by intravenous
injection with siRNA formulated in lipid nanoparticle at 3
or 6mg/kg as previously described (30,33). Animals were
euthanized by CO2 inhalation and immediately after eu-
thanasia liver sections were excised, placed in RNA Later
(Qiagen) and stored at 4 C until ready for analysis. Liver
tissue was homogenized in Qiazol using stainless steel
beads and a TissueLyser (Qiagen). Following homogen-
ization, chloroform was added and samples were
centrifuged. The aqueous layer was combined with an
equal volume of 70% ethanol and samples were puriﬁed
using an RNeasy puriﬁcation kit per manufacturer’s
directions (Qiagen). The resulting RNA was then
normalized, cDNA was synthesized, and RT-qPCR was
performed using ApoB speciﬁc Taqman primer/probe sets
on an ABI Prism 7900HT Sequence Detector. Reverse
transcription conditions were as follows: 60 minutes at
37 C followed by 5min at 95 C. RT–qPCR conditions
were as follows: 2min at 50 C, 10min at 95 C, followed
by 40 cycles of 15s at 95 C and 1min at 60 C. Gapdh
mRNA levels were used for data normalization.
Knockdown of ApoB was calculated using the same
method described for the in vitro experiments.
50-RACE and sequencing of cleavage products
50-RLM-RACE was performed using GeneRacer kit
(Invitrogen) following the manufacturer’s instructions.
Brieﬂy, 100ng untreated RNA was directly ligated to the
RNA linker. After phenol/chloroform extraction and pre-
cipitation, the ﬁrst-strand cDNA was synthesized using
the Oligo-dT primer. For the ﬁrst-round 50RACE
reaction, 1ml of the ﬁrst-strand cDNA was ampliﬁed
using the GeneRacer 50 primer and a target gene speciﬁc
primer (Supplementary Table S5) with cycling as follow-
ing: 1 cycle of 94 C for 2min, then 5 cycles of 94 C for 30s
and 72 C for 1min, and then 5 cycles of 94 C for 30s, and
70 C for 1min, followed by 20 cycles of 94 C for 30s,
65 C for 30s and 68 C for 1min. After additional
10-min incubation at 68 C and cool down to 4 C,mlo f
the ﬁrst PCR reaction was used for the second round
Nucleic Acids Research,2012, Vol.40, No. 9 412750RACE (Nested PCR) using the GeneRacer 50 Nested
primer and gene-speciﬁc nested primer with the 1 cycle
at 94 C for 2min, and 25 cycles of 94 C for 30s, 65 C
for 30s, and 68 C for 1min. From this reaction, 10ml was
analyzed on a 2% agarose gel. See Supplementary Table
S5 for sequence and other information for the primers
used. To conﬁrm the cleavage site of target mRNA, the
gel bands corresponding to the size of the expected
50RACE amplicon was excised and puriﬁed using
QIAquick Gel Extraction kit (QIAGEN). The puriﬁed
PCR products were sequenced by GENEWIZ (South
Plainﬁeld, NJ, USA).
RESULTS
Selection of siRNAs and modiﬁcation patterns
ApoB has been a frequent target of siRNA knockdown
because of its potential therapeutic value in lowering
serum cholesterol. Furthermore, given its predominant
expression in liver hepatocytes, ApoB transcripts can be
readily targeted in vivo using currently available siRNA
delivery technologies (34–36). The Ssb gene encodes the
La antigen which is involved in transfer RNA maturation
(37) and has been implicated in the autoimmune disease
Sjogren’s syndrome (38). Ssb was selected primarily for its
ubiquitous cellular expression pattern. Four siRNAs tar-
geting ApoB and two siRNAs targeting SSB were chosen
to evaluate the generality of our ﬁndings across multiple
siRNAs (Table 1).
Various combinations of ribose (20OH), 20-deoxy (20H),
20-ﬂuoro (20F), and 20-methoxy (20OMe) modiﬁcations
were assigned based on the pyrimidine (Y) or purine (R)
identity of the siRNA sequence (Table 2). Methoxy modi-
ﬁcation of position 14 of the guide strand was not
permitted due to reported sensitivity of this position to
modiﬁcations (17). These combinations were also
evaluated in the presence or absence of 50 phosphorylation
of the guide strand (50PO4). Placement of abasic residues
at the 50 of the guide strand have been reported to reduce
Ago2 binding and cleavage activity (17). Therefore, as a
negative control, a separate set of oligos were synthesized
with three abasic residues (i.e. ribose sugar without nu-
cleotide base) at positions 1–3. The chemical structures
of the 20 modiﬁcations are shown with adenosine as the
representative nucleotide. All together, 30 different siRNA
modiﬁcation patterns were evaluated for each of the ApoB
or SSB target sites (a total of 180 unique guide strands).
Each of the different guide strands was evaluated as single
strands or as duplexes with a passenger strand to create a
conventional siRNA duplex. Passenger strands are largely
ribonucleotides with 20OMe uridine overhangs and
inverted abasic residues on each end. Inverted abasics
block the loading of these strands into Ago2, thus prevent-
ing passenger strand competition with the guide strand
(25,26). Sequence information for each guide strand and
passenger strand are provided in Supplementary Tables S3
and S4. For in vitro studies, all knockdown data were
normalized to a chemically modiﬁed non-speciﬁc siRNA
duplex which was designed to lack homology to nearly all
mammalian transcripts (see ‘Materials and Methods’
section).
20F modiﬁcations are critical for the activity of single
strand RNA in vitro
The mouse hepatocyte derived cell line Hepa1-6 was trans-
fected with single strand and duplex siRNAs at 100 and
10nM concentrations. For dsRNAs, 10nM is likely a
saturating concentration as 100nM did not result in sig-
niﬁcant improvements in observed target knockdown.
Therefore, two siRNAs were also screened at 1nM.
Target knockdown was measured 24h later and
compared to unmodiﬁed controls. Figure 1 shows the
results for ApoB (8786), though a similar trend was
observed for the other ﬁve siRNAs tested
(Supplementary Figure S1). Generally, dsRNAs were
broadly tolerant of modiﬁcations though there was
notable sensitivity to 20-deoxy which is consistent with
Ago2 preference for RNA (rather than DNA) substrates
(13,14). High percentage methoxy modiﬁcation of the
guide strand was tolerated within dsRNAs though a loss
in knockdown was seen at the submaximal 1nM concen-
tration. Such tolerance of methoxy modiﬁcation is likely
Table 2. Summary of modiﬁcation strategy used to evaluate structure–activity relationship for single strand and duplex siRNAs
50 p5 0 aba Pyr (Y) Pur (R) Key Modiﬁcations
+/  +/  20OH 20OH Y=r, R=r
+/  +/  20H2 0H Y=d, R=d
+/  +/  20F2 0F Y=f, R=f
+/  +/  20OMe 20OMe Y=m, R=m
+/  +/  20F2 0OH Y=f, R=r
+/  +/  20F2 0H Y=f, R=d
+/  +/  20F2 0OMe Y=f, R=m
+/  +/  20OH 20F Y=r, R=f
+/  +/  20H2 0F Y=d, R=f
+/  +/  20OMe 20F Y=m, R=f
Oligos were prepared with or without 50 phosphate (50p). Additionally, oligos containing a 50PO4 were tested and with or without three abasic
residues at the 50 end of the guide strand (50aba). Unmodiﬁed ribose (20OH) is compared to 20-ﬂuoro (20F), 20-deoxy (20H), and 20-methoxy (20OMe)
modiﬁcations assigned to pyrimidines (Pyr) or purines (Pur). Key column lists nomenclature used in subsequent ﬁgures. Structures are shown with
adenosine as the representative nucleotide. A total of 30 different siRNAs were designed for each target site. Sequences and modiﬁcation patterns are
listed in Supplementary Table S3.
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guide strand which has previously been reported as
highly sensitive to methoxy modiﬁcations (17).
Strikingly, single strands containing 20F content exhibit
the most pronounced mRNA knockdown of the various
single-strand modiﬁcation patterns tested with 67%
knockdown compared to the negligible activity seen
for unmodiﬁed (Figure 1, Supplementary Table S3). Five
other siRNA sequences were also evaluated and a similar
20F dependence for ssRNA activity was observed, though
the magnitude of response was variable (Supplementary
Figure S1). This variance is likely attributable to the fact
that these RNA oligos were not phosphorylated, and there
is precedent in the literature that 50 phosphorylation of the
guide strand is key for ssRNA knockdown (11,12).
50 phosphorylation improves the potency of ssRNA
The same series of RNA modiﬁcations evaluated in
Figure 1 were then tested in the presence of 50 phosphor-
ylation of the guide strand. Figure 2 shows that addition
of a 50 phosphate signiﬁcantly improves the potency of
ssRNA, resulting in signiﬁcant knockdown even at a
lower concentration of 10nM. The overall effectiveness
of 20F-modiﬁed ssRNA activity for the other ﬁve
siRNAs is also more evident when the ssRNAs are
phosphorylated (Supplementary Figure S2). In the
presence of 50 phosphorylation, the beneﬁcial impact of
20F content is signiﬁcantly more obvious (compare to
Supplementary Figure S1). While the ssRNA knockdown
at this lower concentration still lags that of the
comparable duplex siRNAs, the combination of 20F
modiﬁcations and 50 phosphorylation are key to
improving the potency of ssRNA knockdown:
improving knockdown from negligible levels to 65–95%
(Supplementary Table S3).
Pyrimidines modiﬁed with 20-ﬂuoro appear to confer
improved knockdown to ssRNAs than similarly
modiﬁed purines. It does not seem that overall 20F
content of the RNA oligo can explain this difference as
the ApoB siRNAs are either approximately evenly split
between purine and pyrimidine content or are purine
rich (58% purine). The Ssb sequences are predominantly
pyrimidine rich (58–74%). The underlying mechanism for
20F pyrimidine preference for ssRNA silencing activity
remains unclear. Overall, phosphorylated ssRNAs con-
taining 20F modiﬁcations of both purines and pyrimidines
exhibited the best knockdown activity in vitro.
ssRNA potency signiﬁcantly underperforms
duplex siRNAs
At the two concentrations tested, ssRNAs appear less
potent than their corresponding duplex siRNAs. Two
ApoB siRNAs were selected for dose response measure-
ments and calculation of EC50 values (Figure 3).
Unmodiﬁed and 20F-modiﬁed RNAs were compared as
single strands and duplexes over an eight-point dose–
response ranging from 40nM down to 0.002nM (all
oligos were phosphorylated). The value of 20F modiﬁca-
tions for ssRNA activity was immediately evident for both
ApoB (8786) and (6981) sequences: unmodiﬁed ssRNAs
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Figure 1. Comparison of ssRNA and dsRNA oligos containing pyrimidine (Y) and purine (R) 2’ modiﬁcations. ApoB (8786) sequence shown.
In vitro cell-based evaluation of ApoB mRNA knockdown (error bars represent standard deviation of four replicates). Unmodiﬁed ribose (‘r’) is
compared to 2’-ﬂuoro (‘f’), 2’-methoxy (‘m’), and 2’-deoxy (‘d’) in all combinations on purines (R) and pyrimidines (Y). Oligos do not contain a 5’
phosphate. Guide strand oligo sequence and color-coded modiﬁcation patterns are depicted. Five other siRNAs were tested and a similar require-
ment of 2’F for ssRNA knockdown was observed (Supplementary Figure S1).
Nucleic Acids Research,2012, Vol.40, No. 9 4129essentially had no knockdown over the dose range while
20F ssRNA exhibited a dose response. However, the
duplex siRNAs were found to be 20- to 80-fold more
potent than their corresponding single strands with
picomolar potencies for dsRNAs compared to the
nanomolar potencies measured for ssRNAs
(Supplementary Table S1). ApoB (8786) duplexes
possess 15 pM potencies (for both unmodiﬁed and 20F)
while the 20F ssRNA EC50 is  1.2nM. The ApoB (6981)
20F duplex is  2-fold more potent than the unmodiﬁed
duplex (20OH); however, both are signiﬁcantly more
potent than the 20F ssRNA ( 0.9nM). Despite the
lower overall potencies relative to duplexes, it is important
to note that ssRNAs are still capable of maximal mRNA
knockdown >90% and that this level of knockdown was
enabled by chemical modiﬁcations.
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Figure 2. Comparison of purine versus pyrimidine 20 modiﬁcations for ApoB (8786) in the presence of 50 phosphorylation of the guide strand.
In vitro cell-based evaluation of ApoB mRNA knockdown (error bars represent standard deviation of four replicates). Unmodiﬁed ribose (‘r’) is
compared to 20-ﬂuoro (‘f’), 20-methoxy (‘m’), and 20-deoxy (‘d’) in all combinations on purines (R) and pyrimidines (Y). All RNA oligos contain 50
phosphate (50p). Guide strand oligo sequence and color-coded modiﬁcation patterns are depicted. Five other siRNAs with were also tested with 50
phosphorylation (Supplementary Figure S2) and a similar requirement for 50 phosphorylation for optimal in vitro ssRNA knockdown was observed
(compare to Supplementary Figure S1).
Figure 3. In vitro potency of single strands compared to duplex siRNAs. (A) ApoB (8786) and (B) ApoB (6981) compared as 20OH and 20F guide
strands with 50 phosphorylation. Single strands are  20- to 80-fold less potent than the corresponding duplex siRNAs containing identical guide
strands. Potency and mRNA knockdown values listed in Supplementary Table S1.
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We extended our comparison of ssRNA and dsRNA into
mice to identify whether ssRNAs were competent for
knockdown in vivo. Single strand and duplex RNAs
were formulated in lipid nanoparticles (LNP) which
permitted side by side comparison of these RNAs while
using a well-established delivery vehicle with proven
capabilities (30,32). Since the nanoparticle encapsulates
the siRNAs, it is likely shielded from serum nucleases
which eliminated an additional round of siRNA
chemical optimization for serum stability. The same
ApoB siRNAs assayed for cell-based potency (Figure 3)
were formulated in LNPs and intravenously dosed at
3mg/kg into mice. Three days later the mice were
sacriﬁced and ApoB mRNA knockdown was measured
from harvested livers. Compared to buffer control, the
duplex siRNAs reduced ApoB expression by 85–98%
(Figure 4A and B and Supplementary Table S2).
Unmodiﬁed ssRNAs had no signiﬁcant knockdown
which was consistent with in vitro observations.
However 20F-modiﬁed single strands were quite effective,
reducing ApoB expression levels by 61–74% and
demonstrating that ssRNA functions in vivo.
To evaluate duration of knockdown, a separate in vivo
study was then conducted with the 20F-modiﬁed ssRNA
and dsRNA by using a higher dose (6mg/kg) and con-
ducting a 2-week time-course. Groups of mice were
sacriﬁced at Days 2, 7, and 14, and ApoB mRNA
knockdown was measured (Figure 4C and D). At the
higher dose, ssRNA knockdown increased to nearly
90% at Day 2, although the effect was transient—
knockdown reduced to 71–77% at 7 days and returned
to baseline after 14 days. In marked contrast, duplex
siRNAs still had 95% knockdown two weeks after
dosing. In summary, chemical modiﬁcations permit effect-
ive ssRNA knockdown in vivo and nearly ablate ApoB
expression with an impressive 84–91% knockdown.
However, maximal ssRNA knockdown is transient and
duration activity is exceeded by duplex siRNAs.
Indirect evidence suggests ssRNA acts through
an Ago-mediated mechanism
ssRNA is hypothesized to act through Ago-mediated
mechanisms similar to duplex siRNAs (see ‘Introduction’
section). To address this, we tested a series of modiﬁed
siRNAs where positions 1–3 of the 50-end of the guide
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Figure 4. In vivo knockdown of single strand versus duplex siRNA demonstrates ssRNAi activity in vivo. RNAs formulated in a lipid nanoparticle
(LNP) delivery vehicle. Modiﬁed guide strands (2’F) are compared to unmodiﬁed (2’OH). All oligos contain 5’ phosphorylation. Comparison of Day
3 ApoB mRNA knockdown after an LNP delivered 3mg/kg dose of dsRNA or ssRNA for target sites (A) ApoB (8786) and (B) ApoB (6981).
Knockdown of 60–75% was observed for phosphorylated single strands containing 2’F modiﬁcations. Duration of mRNA knockdown after an LNP
delivered 6mg/kg dose was measured over 2 weeks (Day 2, Day 7, Day 14 time points) for (C) ApoB (8786) and (D) ApoB (6981). Knockdown
values shown in Supplementary Table S2.
Nucleic Acids Research,2012, Vol.40, No. 9 4131strand have been replaced with abasic residues. Abasic
incorporation has previously been reported to adversely
affect Ago2 binding and cleavage activity (17). Both
double-strand siRNA and ssRNA are sensitive to the
incorporation of abasic residues which dramatically
reduce the potency of knockdown for two ApoB
siRNAs when compared to RNA oligos without abasics
(Figure 5A and B). Similar results are seen for all six
siRNAs tested in this study across multiple modiﬁcation
patterns (Supplementary Figure S3). Duplex and ssRNAs
also show a similar sensitivity to 20-deoxy incorporation
(Figure 1 and Supplementary Figure S1). Previously,
similar types of chemical modiﬁcation sensitivity have
been used to argue that ssRNA and dsRNA act through
a common pathway (16).
50RACE identiﬁes only dsRNA cleavage products
Conventional Ago2-mediated cleavage of target mRNA
occurs between positions 9–10 of the region hybridizing
to the guide strand. The PCR-based rapid ampliﬁcation of
cDNA ends (RACE) methodology is routinely applied to
measure the 50-end of the predicted siRNA cleavage
product. PCR primers are designed to produce an
amplicon of predicted size based on the site of siRNA
cleavage of the target mRNA. Two primers are ‘nested’
together in subsequent PCR ampliﬁcations to confer spe-
ciﬁcity to the 50RACE. Two separate PCR amplicons were
designed (Supplementary Table S5) and used for 50RACE
from mouse liver mRNA isolated from animals treated
with ApoB (8786) dsRNA and ssRNA (Figure 4). The
rev1n amplicon should be 319nt and the rev2n amplicon
should be 659nt in size based on the predicted site for
ApoB (8786) cleavage. Both amplicons produce distinct
bands of expected size for samples treated with the
duplex siRNAs (Figure 6A). However, ssRNA treated
samples did not produce a cleavage product despite
yielding 74–91% ApoB knockdown in vivo. Since the
ssRNA and dsRNA samples were ampliﬁed side by side,
we are conﬁdent that the failure to isolate ssRNA cleavage
products is not a technical artifact. Puriﬁcation and
sequencing of a subset of the rev1n amplicons from the
duplex siRNA samples conﬁrmed the predicted Ago2
cleavage site and the presence of the 50RACE primer
(Figure 6B).
DISCUSSION
Chemical modiﬁcations can improve the performance of
ssRNA-mediated knockdown of target mRNAs in vitro
and in vivo. In particular, 20F ribose modiﬁcation and in-
clusion of 50 phosphorylation are required for optimal
ssRNA activity (Figures 1 and 2). However, traditional
duplex siRNAs containing identical guide strands are sig-
niﬁcantly more potent in vitro (Figure 3). Single strand
RNA was compared to siRNA in vivo with lipid
nanoparticle formulated materials dosed intravenously
to mice. While duplex RNAs were consistently more
potent, ssRNA did knockdown ApoB mRNA by up to
90% at a 6mpk dose (Figure 4). This level of ssRNA
knockdown was dependent on chemical modiﬁcations,
as unmodiﬁed ssRNAs possessed no signiﬁcant activity
in vivo despite that the same guide strand was performing
well in the context of a duplex siRNA. Overall, while still
less potent than duplexes, we demonstrate that chemically
optimized ssRNAs are capable of robust mRNA
knockdown in vivo. When coupled with additional
chemical modiﬁcations and alternative dosing regiments,
ssRNA could present signiﬁcant advantages over trad-
itional duplex siRNA (discussed below).
Multiple lines of indirect evidence suggest that ssRNAs
engage an Ago-mediated mechanism for mRNA
knockdown. First, 50 phosphorylation is a requirement
for optimal ssRNA-mediated mRNA knockdown—an
observation consistent across all six siRNAs tested
Figure 5. Inclusion of three abasic residues at positions 1–3 (3aba) of the guide strand decreases the in vitro mRNA knockdown of both duplex and
single strands of ApoB siRNAs. Ribose (2’OH, ‘r’) and ﬂuoro (2’F, ‘f’) oligos with phosphate (5’p) are compared to those containing 3aba for
(A) ApoB (8786) and (B) ApoB (6981). Abasic (3aba) data for additional ApoB and SSB siRNAs are shown in Supplementary Figure S3.
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role of 50 phosphate in ssRNA activity is suggestive of an
Ago-mediated mechanism given the well-characterized
phosphate binding pocket within the MID domain of
Ago2 (13,14). In vitro cleavage assays conducted with
puriﬁed human Ago2 demonstrated that phosphorylated
ssRNAs possessed signiﬁcantly higher cleavage rates than
corresponding ssRNAs without a phosphate (17). A single
abasic at position 1 reduced the binding afﬁnity and
cleavage activity of Ago2 (17) and we found substituting
positions 1–3 of the guide strand with abasic residues was
deleterious to the activity of both duplex siRNAs and
ssRNAs (Figures 5 and S3). Lastly, the length dependence
of ssRNA requiring greater than 17nt for optimal activity
(11) is also similar to the well-characterized Ago2 prefer-
ences for the size of the RNA guide strand (39,40).
Fully modiﬁed 20F RNA ssRNA does not constitute an
RNase H substrate (41,42) and together with the impact of
abasics on ssRNA activity argue against a RNase H
cleavage role. Inclusion of three abasic residues at the 50
of the antisense strand negatively impacts ssRNA-
mediated knockdown despite 16nt of intact bases which
is a strong, but indirect, argument against the involvement
of RNase H. Also, the antisense RNase H-mediated mech-
anism does not require 50 phosphorylation for maximal
activity (41). Lastly, while 20-deoxy is the natural substrate
for RNase H, 20-deoxy modiﬁcations were deleterious for
ssRNA (Figure 2) which argues against an RNase H
mechanism being central to ssRNA activity. However,
we cannot exclude the possibility that ssRNA acts
through multiple pathways employing both RNase H
and Ago-mediated mechanisms.
Despite the evidence for Ago involvement in
ssRNA-mediated knockdown, we were unable to detect
cleavage sites that are hallmarks of Ago2 slicer activity.
Corresponding duplex siRNAs yielded robust cleavage
products with two separate PCR amplicons, and
sequence data support cleavage that occurs at the
expected site (Figure 6). The detection of Ago2 cleavage
products with duplex siRNAs argues that the failure to
detect similar products with ssRNA is not a technical
artifact but rather indicative of the absence of conven-
tional Ago2 cleavage for the ssRNA tested. In vitro
studies with Ago2 highlighted an RNase H activity (17),
so it is intriguing to speculate that 20F ssRNAs could be
participating in an Ago2-mediated cleavage reaction
beyond the hallmark cleavage of the nucleotide bond
opposite positions 10–11 of the guide strand (although
there is no evidence suggesting that DNA guide strands
lead to alternative cleavage sites). Alternatively, ssRNAs
may be complexing with other Ago family members which
do not possess endonucleolytic cleavage activity but still
can mediate knockdown by reducing the stability of the
target mRNA (43). In fact, catalytically inactive mutant
Figure 6. 5’RACE demonstrates duplex RNA, but not ssRNA, cleaves ApoB mRNA producing a cleavage product size consistent with the ApoB
(8786) cleavage site. (A) Agarose gel of two different 5’ RACE products (rev1n and rev2n amplicons; see map of primers) from mRNA puriﬁed from
mouse livers treated with duplex or ssRNA (Figure 4). ApoB (8786) cleavage compared from in vivo mouse livers treated with unmodiﬁed (2’OH) or
2’F-modiﬁed duplex and single strands. (B) Representative sequence data from duplex siRNA cleavage products showing cleavage at the hallmark
site indicative of Ago2 slicer activity and the presence of 5’ RACE primer.
Nucleic Acids Research,2012, Vol.40, No. 9 4133Ago2 has been shown to still maintain silencing activity
(44). Taken together with the observation that
siRNA-mediated target mRNA knockdown retains sig-
niﬁcant potency in the presence of 80% reduction of
Ago2 by antisense oligonucleotides (45), multiple lines of
evidence suggest the presence of a ‘slicer-independent’
mechanism in which ssRNA could be taking part.
The particular mechanism of how 20F content im-
proves the performance of ssRNA remains unclear.
Incorporation of 20F modiﬁcations into siRNAs is
broadly tolerated and may confer beneﬁcial potency and
nuclease stability effects (24,28,46–49). Allerson et al. (24)
identiﬁed an siRNA where the combination of 20F and
20OMe modiﬁcations resulted in greater than 500-fold im-
provement in potency relative to the unmodiﬁed siRNA.
Manoharan et al. (49) found that 20F incorporation
improved siRNA potency approximately 2-fold in vivo.
For the siRNAs tested in this study, 20F content does
not have a pronounced impact on the potency of the
duplex siRNAs. Addition of 20F to ApoB (6981)
improves potency  2-fold (Figure 3), and there is a cor-
responding improvement in vivo (97% knockdown versus
85% for unmodiﬁed). However, there is no beneﬁcial
effect of 20F incorporation in duplex ApoB (8786) either
in vitro or in vivo (Figures 3 and 4). Additionally, 20F
content does not impact the in vitro knockdown of the
four other duplexes tested (Supplementary Table S3).
Therefore, the 20F role appears speciﬁc to ssRNA, suggest-
ing that 20F content contributes to a process prior to Ago2
cleavage (e.g. RNA loading into RISC).
20F pyrimidine modiﬁcations seem more favorable than
corresponding purine modiﬁcations—even in sequences
where pyrimidines are in the minority (Figure 2 and
Supplementary Figure S2). This suggests that the role of
20F in ssRNA is not simply a component of total 20F
content in the RNA molecule. Similar preference for 20F
pyrimidines was observed in a related study evaluating the
activity of single stranded microRNA mimetics
(Guillaume Chorn, Molly Klein-McDowell, Lihong
Zhao, Matthew Saunders, Michael Flanagan, Aarron
Willingham, Lee Lim, manuscript in preparation). In
that study, positions 10 through 19 of miR-124 were
sequence randomized while keeping the seed region
constant and the single strand miR-124 oligos with the
highest activity had elevated pyrimidine content.
Enthalpy-driven enhanced base pairing afﬁnity has been
reported for 20F-modiﬁed RNA (50); however, this would
be expected to improve both duplex and ssRNA perform-
ance which was not broadly seen in this study.
Additional nuclease stability conferred by chemical
modiﬁcations may contribute to the activity of ssRNA.
However, 20H and 20OMe modiﬁcations would be
expected to confer similar beneﬁcial properties to
ssRNA if stability were the sole rate-limiting factor.
20OMe modiﬁcations are somewhat less tolerated in
siRNAs, so the role of 20F in ssRNA could be a combin-
ation of stability and broader tolerance. Overall the
number of fully modiﬁed RNA oligos which are function-
al as dsRNA and not as ssRNA suggests that the 20F
improvement of ssRNA activity likely relies on properties
beyond nuclease stability.
Further optimization and development of ssRNA
with increased potency may result in a differentiating tech-
nology. Eliminating the passenger strand reduces synthesis
cost by half and also halves the charge of the molecule
which may aid in tissue biodistribution and cellular per-
meability. Intravenous or subcutaneous delivery of unfor-
mulated ssRNAs could beneﬁt from the same
pharmokinetic and toxicology properties of traditional
antisense technology which itself has been successfully
applied in late stage clinical trials in humans. Lastly,
ssRNAs would not be susceptible to competition from
non-speciﬁc double-strand binding proteins such as ad-
enosine deaminases (ADAR) which have been reported
to interfere with siRNA knockdown in speciﬁc tissues
(51,52). The unpublished work of Swayze et al. (23) on
the in vivo performance of an optimized ssRNA molecule
is quite encouraging and highlights the potential value of
‘next generation’ ssRNA. However, it remains to be seen
whether ssRNAs can confer beneﬁcial drug-like properties
beyond those currently available with either antisense
oligonucleotides or duplex siRNAs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables S1–S5 and Supplementary Figures
S1–S3.
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